Advertisement

Topics

EHA 2019: Phase 3 randomised study of daratumumab plus D-VTd vs VTd in transplant-eligible newly diagnosed multiple myeloma

03:48 EDT 14 Jun 2019 | ecancermedicalscience

Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell transplantation (ASCT) is standard treatment in Europe for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). It was evaluated whether the addition of...

Original Article: EHA 2019: Phase 3 randomised study of daratumumab plus D-VTd vs VTd in transplant-eligible newly diagnosed multiple myeloma

NEXT ARTICLE

More From BioPortfolio on "EHA 2019: Phase 3 randomised study of daratumumab plus D-VTd vs VTd in transplant-eligible newly diagnosed multiple myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...